Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $30,281.02 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 19,663 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $1.54, for a total transaction of $30,281.02. Following the sale, the insider owned 128,681 shares in the company, valued at $198,168.74. The trade was a 13.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Julie Green also recently made the following trade(s):

• On Wednesday, February 18th, Julie Green sold 20,964 shares of Invivyd stock. The stock was sold at an average price of $1.58, for a total transaction of $33,123.12.

Invivyd Price Performance

Shares of NASDAQ:IVVD opened at $1.55 on Friday. Invivyd, Inc. has a 1 year low of $0.46 and a 1 year high of $3.07. The stock has a market capitalization of $361.34 million, a price-to-earnings ratio of -3.30 and a beta of 0.60. The company’s 50 day simple moving average is $2.16 and its 200 day simple moving average is $1.76.

Hedge Funds Weigh In On Invivyd

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in shares of Invivyd by 190.6% during the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after purchasing an additional 71,485 shares during the period. AQR Capital Management LLC raised its position in Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after purchasing an additional 391,617 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its position in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after purchasing an additional 28,146 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new position in Invivyd during the 2nd quarter worth about $27,000. Finally, Marshall Wace LLP bought a new stake in shares of Invivyd in the 2nd quarter valued at about $158,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IVVD has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Finally, HC Wainwright boosted their target price on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.